According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned stocks have outperformed the S&P 500 Index over the past 12 months as of March 31.
Axsome Therapeutics
Axsome Therapeutics Inc. (AXSM, Financial) has a market cap of $2.11 billion. It has outperformed the S&P 500 by 312% over the past year.
Shares are trading with a price-book ratio of 11.08. As of Tuesday, the share price was 659% above the 52-week low and 47.22% below the 52-week high.
The health care service provider has a profitability rating of 1 out of 10. The return on equity of -149% and return on assets of -90% are underperforming 83% of companies in the biotechnology industry. Its financial strength is rated 5 out of 10. The cash-debt ratio of 11.03 is above the industry median of 8.24.
Chuck Royce (Trades, Portfolio) is the company's largest guru shareholder with 0.16% of outstanding shares, followed by Jim Simons (Trades, Portfolio)’ Renaissance Technologies with 0.14% and Paul Tudor Jones (Trades, Portfolio) with 0.06%.
ChemoCentryx
With a market cap of $2.44 billion, ChemoCentryx Inc. (CCXI, Financial) has outperformed the S&P 500 by 192% over the past 12 months.
Shares are trading with a price-book ratio of 34.15. As of Tuesday, the price was 545% above the 52-week low and 22.59% below the 52-week high.
The biopharmaceutical company has a profitability rating of 1 out of 10. While the return on equity of -94% is underperforming the sector, the return on assets of -25% is outperforming 61% of companies in the biotechnology industry. Its financial strength is rated 5 out of 10. The cash-debt ratio of 8.12 is below the industry median of 8.24.
The company’s largest guru shareholder is Simons’ firm with 1.32% of outstanding shares, followed by Joel Greenblatt (Trades, Portfolio) with 0.02%.
DexCom
Dexcom Inc. (DXCM, Financial) has a market cap of $25.18 billion. It has outperformed the S&P 500 by 141% over the past year.
Shares are trading with a price-earnings ratio of 254. According to the DCF calculator, the stock is largely overpriced by 2,200% at $268. As of Tuesday, the price was 149.87% above the 52-week low and 12.47% below the 52-week high.
The company, which manufactures systems to monitor glucose level for diabetics, has a profitability rating of 3 out of 10. The return on equity of 13.78% and return on assets of 4.8% are outperforming 69% of companies in the medical diagnostics and research industry. Its financial strength is rated 6 out of 10. The cash-debt ratio of 1.32 is above the industry median of 1.31.
The company’s largest guru shareholder is Steve Mandel (Trades, Portfolio) with 2.30% of outstanding shares, followed by Simons’ firm with 0.76% and Ron Baron (Trades, Portfolio) with 0.56%.
Eidos Therapeutics
With a market cap of $1.88 billion, Eidos Therapeutics Inc. (EIDX, Financial) has outperformed the S&P 500 by 116% over the past 12 months.
Shares are trading with a price-book ratio of 10.69. As of Tuesday, the price was 190.46% above the 52-week low and 26.38% below the 52-week high.
The biopharmaceutical company has a profitability rating of 1 out of 10. The return on equity of -24.68% and return on assets of -22.65% are outperforming 66% of companies in the biotechnology industry. Its financial strength is rated 5 out of 10. The cash-debt ratio of 8.99 is above the industry median of 8.24.
The company’s largest guru shareholder is Steven Cohen (Trades, Portfolio) and Simons’ firm with 0.02%.
Enphase Energy
Enphase Energy Inc. (ENPH, Financial) has a market cap of $3.96 billion. It has outperformed the S&P 500 by 254% over the past 12 months.
Shares are trading with a price-earnings ratio of 26.81. According to the DCF calculator, the stock is overpriced by 143% at $32 per share. As of Tuesday, the price was 321% above the 52-week low and 42.91% below the 52-week high.
The company has a profitability rating of 2 out of 10. The return on equity of 142.94% and return on assets of 33.89% are outperforming 99% of companies in the semiconductors industry. Its financial strength is rated 7 out of 10. The cash-debt ratio of 2.31 is below the industry median of 1.38.
The company’s largest guru shareholder is Simons’ firm with 1.70% of outstanding shares, followed by Louis Moore Bacon (Trades, Portfolio) with 0.10% and Royce with 0.07%.
Disclosure: I do not own any of the stocks mentioned.
Read more here:
- 5 Undervalued Stocks Trading Below Peter Lynch Value
- 6 Banks Trading With Low Price-Sales Ratios
- 5 High-Yielding Stocks Trading With Low Price-Earnings Ratios
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
